Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.

ABSTRACT:

Background

Many cognitively unimpaired older adults are interested in learning their Alzheimer's disease (AD) biomarker status, but little is known about motivations to undergo biomarker testing and result disclosure in the setting of preclinical AD trials.

Objectives

Examine whether motivations to undergo AD biomarker testing and disclosure differ for individuals who have elevated amyloid compared to those with not elevated amyloid, and whether disclosure of amyloid results impacts participants' motivations.

Design, setting, participants

We conducted post-hoc analyses using data from the EARLY study, a preclinical AD trial of the beta-secretase inhibitor atabecestat. As part of the screening process of the trial, participants underwent biomarker testing and disclosur

SUBMITTER: Ritchie M 

PROVIDER: S-EPMC11573807 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature